SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin,
compared to metformin on annual decline in eGFR when used as first line therapy in people
with recently diagnosed Type 2 Diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
The George Institute
Collaborators:
Monash University The University of New South Wales University of Sydney